Off-the-shelf NK cell therapy enters the picture
Allogeneic NK-cell therapy programs are reading out across haematological and solid-tumour indications.
Off-the-shelf NK cell therapy is the next modality test after CAR-T and bispecifics. The clinical case is positioned around the lower toxicity profile and faster time-to-infusion versus autologous CAR-T. Whether durable responses match the autologous benchmark is what the next 18 months of pivotal data will determine.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
TreatmentPipelineDrug developmentDelivery
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.